Zambart and its collaborating partner Centre for Infectious Diseases in Zambia (CIDRZ) in the Phase IIb trial of a new tuberculosis vaccine awaiting activation, held a two-day training for TB community advocates at Lusaka’s Cresta Golfview Hotel.
50 community engagement advocates drawn from various community based organisations in Lusaka’s Kanyama and Kalingalinga compounds, the study sites for the vaccine trial, attended the workshop, which was aimed at strengthening community engagement and advocacy capacity on TB treatment.
The trial also called TB 018, is being jointly conducted by Aeras and GlaxoSmithkline Vaccines, S.A. (GSK), and is a double-blind, randomised placebo-controlled study. Overall, the trial will enrol more than 3500 healthy adults, with latent (asymptomatic) TB infection (LTBI), ages 18-50 in three sub-Saharan African countries namely Zambia, Kenya, and South Africa.
Zambart has been conducting various clinical trials in TB in Zambia and beyond, for over 2 decades now.